Optimising the evaluation of therapeutic response to first-line treatment of diffuse large B cell lymphoma Article à paraître

Figure 1

Complementarity of metabolic and molecular assessments of minimal residual disease over time.

Figure 2

Illustration of an adaptive prognostic model based on baseline (amount of ctDNA, IPI, GCB/ABC subtype) and treatment data (iPET, major and early molecular responses, MMR, EMR). (adapted from [23]).